Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER_GOV × Small Cell Lung Cancer Recurrent × Clear all

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 Carcinoma, Non-Small-Cell Lung 29 Stomach Neoplasms 26 Colorectal Neoplasms 19 Small Cell Lung Carcinoma 17 Lung Neoplasms 16 Rectal Neoplasms 14 Neoplasm Metastasis 14 Pancreatic Neoplasms 12 Neoplasms 12 Esophageal Neoplasms 11 Ovarian Neoplasms 10 Nasopharyngeal Carcinoma 10 Uterine Cervical Neoplasms 9 Recurrence 9 Leukemia, Myeloid, Acute 9 Carcinoma, Hepatocellular 9 Melanoma 7 Lymphoma, Non-Hodgkin 7 Triple Negative Breast Neoplasms 6 Hodgkin Disease 6 Head and Neck Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Colonic Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Neoplasms, Germ Cell and Embryonal 5 Lymphoma, Large B-Cell, Diffuse 5 Lymphoma 5 Cholangiocarcinoma 5 Adenocarcinoma of Lung 5

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡